Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Eaton Corporation: Portfolio Transformation and The Cost of Capital (Abridged)
Esty, Benjamin C.; Mayfield, E. Scott; Fisher, DanielCaso HBS-221070-EFinanzasIn 2000, Eaton Corporation was a broadly diversified industrial conglomerate. But its strategy was evolving and its focus was narrowing around "power management" and more recently on "intelligent power," the use of digitally enabled products and services designed to enhance efficiency and reliability. To implement this transition, Eaton had acquired more than 70 companies and divested another 50. Such active portfolio management required Eaton to...Desde 8,20 €
-
United Technologies: Are the Parts Worth More Than the Whole
Esty, Benjamin C.; Fisher, DanielCaso HBS-220018-EFinanzasAfter spending more than 50 years creating a diversified industrial conglomerate that Fortune Magazine described as "arguably the most profitable conglomerate in America" in 2014, UTC's CEO Greg Hayes was under pressure from activist investors (Dan Loeb aDesde 8,20 €
-
Impax Laboratories: Executing Accretive Acquisitions (B)
Esty, Benjamin C.; Fisher, DanielCaso HBS-220031-EFinanzasIExplores events after Impax announced the acquisition of a portfolio of generic pharmaceutical products from Teva in June 2016.Desde 5,74 €
-
Impax Laboratories: Executing Accretive Acquisitions (A)
Esty, Benjamin C.; Fisher, DanielCaso HBS-220030-EFinanzasImpax Laboratories was a technology-based pharmaceutical company that used a "dual platform" strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the early morning of June 21, 2016, the firm issued a press release announcing it was buying a portfolio of generic drugs from Teva for $586 million in cash. The leadership team (CEO, CF...Desde 8,20 €